[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Chalastras T, Elefteriadou A, Giotakis J, Soulandikas K, Korres S, Ferekidis E, Kandiloros D: Non-Hodgkin's lymphoma of nasal cavity and paranasal sinuses. A clinicopathological and immunohistochemical study. Acta Otorhinolaryngol Ital; 2007 Feb;27(1):6-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overall 12 patients with non-Hodgkin malignant lymphoma, at our Institute, were studied over an eight-year period from 1997 to 2005.
  • Patients' data collected were age, sex, presenting signs and symptoms, histology, treatment, complications, and outcome.
  • Also available were computerised tomography findings, and paraffin-embedded tissue bocks.
  • Using immunocytochemistry on paraffin-embedded tissue sections, the predominance of large B-cell subtype was detected.
  • Treatment administered: only radiotherapy (stage IEA) or in combination with chemotherapy (IIE-IVE).
  • Early diagnosis, based mainly on tissue biopsy and computerised tomography, is essential in the management of non-Hodgkin lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / radiography. Paranasal Sinus Neoplasms / immunology. Paranasal Sinus Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Male. Middle Aged. Nasal Cavity. Neoplasm Staging. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Aug;124(8):1213-6 [10923086.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 Apr;108(4):411-9 [10214792.001]
  • [Cites] Auris Nasus Larynx. 2001 Jan;28(1):55-60 [11137364.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Mar;97(3):328-31 [15024355.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):768-76 [4016670.001]
  • [Cites] Pathology. 1986 Oct;18(4):419-25 [3493470.001]
  • [Cites] Lancet. 1988 Feb 6;1(8580):292-3 [2893097.001]
  • [Cites] Hum Pathol. 1989 Jul;20(7):636-42 [2661407.001]
  • [Cites] Am J Surg Pathol. 1991 Mar;15(3):268-79 [1996731.001]
  • [Cites] CA Cancer J Clin. 1993 Jan-Feb;43(1):7-26 [8422609.001]
  • [Cites] Blood. 1993 May 15;81(10):2688-95 [8387835.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1994 Apr;103(4 Pt 1):294-300 [8154771.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1281-91 [7882278.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):477-88 [9241082.001]
  • [Cites] Laryngoscope. 2000 Sep;110(9):1489-92 [10983948.001]
  • (PMID = 17601204.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2640014
  •  go-up   go-down


2. Nishino H, Ichimura K, Tanaka H, Ishikawa K, Abe K, Fujisawa Y, Shinozaki T: Results of orbital preservation for advanced malignant maxillary sinus tumors. Laryngoscope; 2003 Jun;113(6):1064-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of orbital preservation for advanced malignant maxillary sinus tumors.
  • OBJECTIVE: The purpose of the study was to examine the oncological and functional outcomes of multimodality therapy for patients with advanced malignant maxillary sinus tumors that invaded the orbit.
  • All patients underwent simultaneous combined therapy consisting of conservative surgery through a sublabial incision, radiotherapy, and regional chemotherapy.
  • CONCLUSIONS: Combined therapy with conservative surgery, radiotherapy, and regional chemotherapy is an effective method for local control and preservation of ocular function.
  • However, performing orbital conservation procedure in patients with disease other than squamous cell carcinoma and with orbital apex disease must be considered carefully.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Maxillary Sinus Neoplasms / therapy. Orbital Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12782824.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Preś K, Pośpiech L, Krecicki T, Nadolska B, Kubacka M, Zatoński T, Jabłonka A, Piechnik-Resler D, Jankowska-Konsur A: [Malignant neoplasm of nose and paranasal sinuses in Lower Silesia in years 1992-2001]. Wiad Lek; 2006;59(11-12):797-800
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant neoplasm of nose and paranasal sinuses in Lower Silesia in years 1992-2001].
  • Malignant neoplasms of the nose and paranasal sinuses occur rarely but due to late diagnosis and poor treatment effects still remain a serious problem.
  • The aim of the study was the analysis of all nose and paranasal sinus neoplasms treated at Lower Silesia in the years 1992-2001.
  • MATERIAL AND METHODS: In the years 1992-2001 in Lower Silesia region there were 182 patients treated for malignant nose and paranasal sinus tumors.
  • Principal management was combined therapy--surgery with radiotherapy in 84% of the cases.
  • Radiotherapy alone was performed in 8.8% and chemotherapy as palliative treatment in 7.1%.
  • CONCLUSIONS: Unsatisfactory results of treatment are an effect of a high advanced stage of the tumor while diagnosed.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / therapy. Nose Neoplasms / epidemiology. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / epidemiology. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Neoplasm Staging / classification. Nose. Poland / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Sex Distribution. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17427494.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


Advertisement
4. Jurkiewicz D, Wojdas A, Hermanowski M: [Malignant tumors of the nose and paranasal sinuses in the years 1971-2005 in the material of the Otolaryngology Clinic WIM]. Otolaryngol Pol; 2007;61(4):572-5
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant tumors of the nose and paranasal sinuses in the years 1971-2005 in the material of the Otolaryngology Clinic WIM].
  • The aim of this study was retrospective analysis of evidence concerning to malignant tumors of the nasal cavity and the paranasal sinuses diagnosed in Otolaryngology Clinic of the Military Institute of the Health Service 1971-2005.
  • The methods of therapy were also discussed.
  • MATERIAL AND METHODS: Material comprised 113 patients (35 females and 78 males) with diagnosis of malignant tumors of the nose and paranasal sinuses.
  • The clinical aspects, sex, age, TNM classification and therapy methods (surgery, radiotherapy, chemotherapy) were analysed.
  • In 89 subjects (23 females and 66 males) the neoplasm of epithelial origin were diagnosed.
  • Three of patients did not agree for therapy.
  • CONCLUSIONS: The most frequent of malignant tumors of the nose and paranasal sinuses was cancer.
  • The clinical symptoms of tumor were disclosed most often in age of 60-80 years.
  • The method of choice in treatment is surgery combined with postoperative radiation.
  • [MeSH-major] Nose Neoplasms / epidemiology. Paranasal Sinus Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Poland / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260254.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


5. Handel LN, Scott SM, Giller RH, Greffe BS, Lovell MA, Koyle MA: New perspectives on therapy for vaginal endodermal sinus tumors. J Urol; 2002 Aug;168(2):687-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New perspectives on therapy for vaginal endodermal sinus tumors.
  • PURPOSE: Malignant germ cell tumors account for 3% of childhood cancers.
  • Endodermal sinus tumor, the most common malignant germ cell tumor, requires treatment primarily with chemotherapy and surgery is reserved as a last resort.
  • It is rare for the vagina to be the primary site of endodermal sinus tumor, and we report on our experiences with this phenomenon at a single institution.
  • MATERIALS AND METHODS: We retrospectively reviewed the clinical features, treatment and outcomes of 3 children with vaginal endodermal sinus tumor.
  • RESULTS: Initial treatment was combination chemotherapy, in 2 patients. alpha-fetoprotein decreased rapidly and returned to normal in both.
  • One patient is disease-free 7 years after chemotherapy and the other patient is currently disease-free with a normal alpha-fetoprotein 3 months after induction chemotherapy.
  • In the remaining case progressive disease developed following initial chemotherapy and subsequent salvage surgery combined with radiation, chemotherapy and ultimately autologous bone marrow transplant was performed.
  • The patient has remained disease-free for 6.5 years since completing this extensive therapy.
  • CONCLUSIONS: Endodermal sinus tumor of the vagina is rare.
  • Bone marrow transplant should be considered as a last therapeutic resort in salvage cases of unresponsive vaginal endodermal sinus tumor.
  • [MeSH-major] Endodermal Sinus Tumor / therapy. Vaginal Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies. Salvage Therapy. Survival Rate. Vagina / pathology

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12131350.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Arndt S, Echternach M, Aschendorff A, Schipper J, Maier W: [Malignant rhino- and otobasal mucosal melanomas--therapy and outcome]. Laryngorhinootologie; 2008 Jun;87(6):412-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant rhino- and otobasal mucosal melanomas--therapy and outcome].
  • BACKGROUND: Malignant melanoma of the rhinobasal mucosa is very rare and makes up less than one percent of all malignant melanomas.
  • During the past two decades, a variety of therapeutic modalities has been proposed.
  • MATERIALS AND METHODS: In a retrospective quality assessment, we analysed the charts of fifteen consecutive patients suffering from malignant melanoma of the skull base who where treated in our department since 1993.
  • The influence of specific surgical and adjuvant therapy on recurrence and outcome was evaluated.
  • Thus, melanoma was an accidental finding of a biopsy or sinus surgery in most patients, including all cases with amelanotic melanoma.
  • All patients underwent surgery as the initial treatment, in 8 cases followed by adjuvant therapy.
  • CONCLUSION: We conclude from our data and analysis of literature that the prognosis of MM has not developed favourably during the past two decades.
  • Radiation therapy and adjuvant immuno- or chemotherapy seems to have a positive impact.
  • [MeSH-major] Melanoma / surgery. Nose Neoplasms / surgery. Palatal Neoplasms / surgery. Paranasal Sinus Neoplasms / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Interferon-alpha / therapeutic use. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Orbit Evisceration. Palliative Care. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18506652.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


7. Palenzuela G, Martin E, Meunier A, Beuzeboc P, Laurence V, Orbach D, Frappaz D: Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary. Ann Surg; 2008 Nov;248(5):836-41
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary.
  • BACKGROUND: The management of malignant germ cell tumors of the ovary (OMGCT) requires multidisciplinary expertise.
  • PATIENTS AND METHODS: Data concerning diagnosis, surgery, and medical decisions were reviewed for all patients seen for postoperative management of OMGCT at the Centre Léon Bérard in Lyon and the Institut Curie in Paris between 1985 and 2003.
  • Sixty patients aged 0.4 to 27.9 years (mean 12.8 years) at diagnosis were included.
  • Relapses occurred in 8 of 24 stage I tumors that were observed (0/8 stage Ia; 5/13 stage Ix (P = 0.044) and 3/3 stage Ic) versus 0/14 stage I treated by adjuvant chemotherapy (P = 0.0015).
  • The risk of relapse was significantly increased if patients underwent postsurgical observation ((HR) = 4.5 (95% CI, 1.5 to 13.3)), and when the tumor contained yolk sac tumor (HR = 7.3 (95% CI, 2.3 to 22.7)).
  • There was no significant prognostic value for age, stage, level of tumor markers at diagnosis, type of surgery, and type of chemotherapy.
  • CONCLUSION: Comprehensive staging after removal of localized OMGCT is crucial.
  • Patients with stages Ix and Ic tumors may benefit from adjuvant chemotherapy.
  • [MeSH-minor] Chemotherapy, Adjuvant. Child. Dysgerminoma / diagnosis. Dysgerminoma / surgery. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / surgery. Fallopian Tubes / surgery. Female. Humans. Neoplasm Staging. Ovariectomy. Radiotherapy, Adjuvant. Retrospective Studies. Teratoma / diagnosis. Teratoma / pathology. Teratoma / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18948812.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


8. El-Lamie IK, Shehata NA, Abou-Loz SK, El-Lamie KI: Conservative surgical management of malignant ovarian germ cell tumors: the experience of the Gynecologic Oncology Unit at Ain Shams University. Eur J Gynaecol Oncol; 2000;21(6):605-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative surgical management of malignant ovarian germ cell tumors: the experience of the Gynecologic Oncology Unit at Ain Shams University.
  • PURPOSE: To evaluate the role of extended surgical staging in patients with malignant ovarian germ cell tumors in the presence of cisplatinum-based combination chemotherapy.
  • MATERIALS & METHODS: 16 patients aged between 13 and 40 years (mean 20.5) diagnosed and treated for malignant ovarian germ cell tumors at the Gynecologic Oncology Unit.
  • RESULTS: Six patients were diagnosed with dysgerminoma, six with immature teratoma and four with endodermal sinus tumor.
  • Only seven cases were primarily managed at the unit and were subjected to proper surgical staging as required by FIGO (two in each of the stages IC, IIC and IIIA and one in stage IV).
  • However, the remaining nine cases were referred to the unit, six after having unilateral salpingo-oophorectomy and no surgical staging, one patient after total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH+BSO), and one with recurrent dysgerminoma in the retroperitoneum and mediastinum following suboptimal treatment.
  • None of these cases were surgically re-explored and all including the first six cases were given the standard BEP chemotherapy for 4-6 courses (mean 5.8).
  • All patients are alive without any evidence of disease recurrence except for one patient with a stage IIIA immature teratoma who had a local and distant recurrence and is undergoing second-line chemotherapy.
  • The role of revisional surgical staging, in particular retroperitoneal lymphadenectomy in light of these data and those of others should be redefined in the future.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Germinoma / surgery. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Egypt. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Neoplasm Staging. Reoperation. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11214621.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


9. Skof E, Grasic Kuhar C, Cerar O, Zakotnik B: Survival and fertility of patients with malignant ovarian germ cell tumours. Eur J Gynaecol Oncol; 2004;25(6):702-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and fertility of patients with malignant ovarian germ cell tumours.
  • Disease-free survival (DFS), overall survival (OS) and fertility of patients treated for malignant ovarian germ cell tumours at the Institute of Oncology Ljubljana from 1990-2000 were assessed.
  • Five had pure dysgerminoma, three endodermal sinus tumour, ten immature teratoma and five had mixed germ cell tumours.
  • Twenty-one patients received adjuvant cisplatin-based chemotherapy.
  • Six patients (two did not receive adjuvant chemotherapy) relapsed at a median of 16 (3-63) months after surgery.
  • At relapse four were treated with surgery and chemotherapy, one with chemotherapy only and one with palliative radiotherapy only: two are still in complete remission, one has residual disease and three died of disease.
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Slovenia / epidemiology. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15597846.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB: Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck; 2002 Sep;24(9):821-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant tumors of the nasal cavity and paranasal sinuses.
  • PURPOSE: To evaluate the role of radiation therapy in patients with nasal cavity and paranasal sinus tumors.
  • MATERIALS AND METHODS: Between October 1964 and July 1998, 78 patients with malignant tumors of the nasal cavity (48 patients), ethmoid sinus (24 patients), sphenoid sinus (5 patients), or frontal sinus (1 patient) were treated with curative intent by radiation therapy alone or in the adjuvant setting.
  • Forty-seven patients were treated with irradiation alone, 25 with surgery and postoperative irradiation, 2 with preoperative irradiation and surgery, and 4 with chemotherapy in combination with irradiation with or without surgery.
  • Of the 67 (86%) patients who were initially seen with node-negative disease, 39 (58%) received no elective neck treatment, and 28 (42%) received elective neck irradiation.
  • Of the 39 patients who received no elective neck treatment, 33 (85%) did not experience recurrence in the neck compared with 25 (89%) of 28 patients who received elective neck irradiation.
  • CONCLUSION: Surgery and postoperative radiation therapy may result in improved local control, absolute survival, and complications when compared with radiation therapy alone.
  • [MeSH-major] Carcinoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blindness / etiology. Blindness / prevention & control. Cause of Death. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Osteoradionecrosis / etiology. Postoperative Care. Preoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc. Head Neck 24: 821-829, 2002
  • (PMID = 12211046.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Bakri YN, Ezzat A, Akhtar, Dohami, Zahrani: Malignant germ cell tumors of the ovary. Pregnancy considerations. Eur J Obstet Gynecol Reprod Biol; 2000 May;90(1):87-91
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant germ cell tumors of the ovary. Pregnancy considerations.
  • OBJECTIVE: To study the pregnancy association and malignant germ cell tumors of the ovary with regard to its effects on tumor prognosis.
  • STUDY DESIGN: : Seventy-five patients with malignant germ cell tumors of the ovary treated at the King Faisal Specialist Hospital-Research Center (KFSH-RC) Riyadh, Kingdom of Saudi Arabia between January 1976 and December 1992, were reviewed.
  • Data was retrieved from the medical records and the database of ovarian tumor pathology.
  • Patients with tumor/pregnancy association were identified and correlation with obstetrical outcome and tumor prognosis analyzed.
  • Patients who conceived after treatment were identified and their reproductive outcome described.
  • RESULTS: Malignant germ cell tumor was associated with pregnancy in a group of ten patients.
  • Possible tumor effects upon pregnancy in this group included operative delivery by caesarean section (n=3), mid-trimester termination (n=2), spontaneous abortion (n=1).
  • Four patients had normal vaginal birth with no apparent tumor effects upon pregnancy.
  • Pregnancy did not seem to influence the tumor prognosis of pure dysgerminoma (n=6), however, two patients with non-dysgerminomatous germ cell tumor (one endodermal sinus tumor and one immature teratoma) died of rapidly progressive disease during the second trimester.
  • Two patients with advanced (stage IIIC) disease concurrent with pregnancy (one pure dysgerminoma and one mixed germ cell tumor), had normal fetal outcomes and achieved long-term survival.
  • Amongst the 22 patients who planned to conceive after conservative surgery, with or without post-operative adjuvant chemotherapy, 12 conceived (12/22) and achieved a total of 20 pregnancies.
  • CONCLUSIONS: Our findings suggest that, (1) The association of pure dysgerminoma and pregnancy did not adversely affect the tumor prognosis or fetal outcome.
  • However, the question remains as to whether pregnancy worsened the prognosis of non-dysgerminomatous germ cell tumors. (2) Recent platinum-based regimens of multiagent chemotherapy for germ cell tumors did not seem to affect fertility potential.
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Middle Aged. Neoplasm Staging. Pregnancy. Pregnancy Outcome. Reproductive History

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10767517.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] IRELAND
  •  go-up   go-down


12. Khademi B, Moradi A, Hoseini S, Mohammadianpanah M: Malignant neoplasms of the sinonasal tract: report of 71 patients and literature review and analysis. Oral Maxillofac Surg; 2009 Dec;13(4):191-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant neoplasms of the sinonasal tract: report of 71 patients and literature review and analysis.
  • BACKGROUND: The present study aimed to report the characteristics, prognostic factors, and treatment outcomes of 71 cases of malignant neoplasms of the sinonasal tract and literature review and analysis of major report series.
  • METHODS: Seventy-one consecutive patients diagnosed with primary malignant neoplasm of the sinonasal tract that were treated and followed up at a university hospital between May 2000 and March 2008 were selected for the present study.
  • Thirty-four patients were treated with surgery followed by a combination of chemotherapy and radiotherapy, 15 with surgery alone, 14 with combined radiotherapy and chemotherapy, six with radiotherapy alone, and two with surgery followed by radiotherapy.
  • In all, we found 42 major series including 8,164 patients with malignant neoplasms of the sinonasal tract.
  • RESULTS: There were 35 women and 36 men ranging in age from 5 to 80 years, with a median age of 55 years at diagnosis.
  • Local recurrence was the most frequent treatment failure.
  • On univariate analysis, cervical lymph nodes involvement, primary tumor size, histologic type, response to therapy, and stage of disease were independent prognostic factors for overall survival.
  • Epithelial tumors consisted of 69% of all malignant neoplasms of sinonasal tract and stages III and IV disease constituted 74.7% of all stages.
  • Local recurrence was the dominant treatment failure in nearly all series.
  • CONCLUSIONS: In this review and by analyzing the large data collection of recent major reported series, we found that malignant neoplasms of the sinonasal tract tend to present at locally advanced stage, with a high frequency of local failure and a moderate to poor outcome.
  • More effective local treatment for improving the local control and overall survival is needed.
  • [MeSH-major] Carcinoma / pathology. Nose Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Cisplatin / therapeutic use. Cobalt Radioisotopes / therapeutic use. Disease-Free Survival. Female. Fluorouracil / therapeutic use. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Proportional Hazards Models. Radiography. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Med Assoc. 2007 Dec;99(12):1407-10 [18229778.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):948-55 [15313865.001]
  • [Cites] Head Neck. 1998 Mar;20(2):97-105 [9484939.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Am J Rhinol. 1999 Mar-Apr;13(2):117-23 [10219440.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1042-50 [17570610.001]
  • [Cites] Acta Oncol. 1997;36(1):45-50 [9090965.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):141-7 [17459609.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1992 Mar;14(2):135-7 [1618083.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 1;67(3):691-702 [17161557.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2005 Feb;27(2):117-21 [15946555.001]
  • [Cites] J Laryngol Otol. 1980 Mar;94(3):301-9 [7373133.001]
  • [Cites] Otolaryngol Pol. 2008;62(4):436-41 [18837219.001]
  • [Cites] HNO. 2005 Nov;53(11):957-65 [15883842.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2009 Feb;135(2):173-9 [19221246.001]
  • [Cites] Wiad Lek. 2006;59(11-12):797-800 [17427494.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1991 Mar;3(2):84-9 [2031888.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Apr;122(4):499-508 [10740168.001]
  • [Cites] Tumori. 1986 Dec 31;72(6):589-95 [3810867.001]
  • [Cites] Head Neck. 2000 Dec;22(8):772-80 [11084637.001]
  • [Cites] Acta Oncol. 1997;36(1):27-31 [9090960.001]
  • [Cites] Laryngoscope. 2009 May;119(5):899-906 [19358246.001]
  • [Cites] Radiol Med. 1994 Sep;88(3):291-4 [7938737.001]
  • [Cites] J Laryngol Otol. 2007 Jan;121(1):49-56 [16995961.001]
  • [Cites] CA Cancer J Clin. 2005 Jul-Aug;55(4):242-58; quiz 261-2, 264 [16020425.001]
  • [Cites] Laryngorhinootologie. 1991 Mar;70(3):138-41 [2036148.001]
  • [Cites] Acta Radiol Oncol. 1984;23(2-3):181-7 [6331089.001]
  • [Cites] Zhonghua Er Bi Yan Hou Ke Za Zhi. 2000 Jun;35(3):168-71 [12768768.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1343-51 [18963535.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Otolaryngol Pol. 2000;54(1):13-5 [10822961.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):424-32 [18755554.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 2006 Jun;123(3):115-9 [16840900.001]
  • [Cites] Jpn J Clin Oncol. 1995 Oct;25(5):188-94 [7474406.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Sep;128(9):1079-83 [12220216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):27-35 [10924968.001]
  • [Cites] Curr Oncol Rep. 2007 Mar;9(2):147-51 [17288882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):51-8 [15093898.001]
  • [Cites] Acta Otorrinolaringol Esp. 2006 Oct;57(8):359-63 [17117693.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2214-23 [14601092.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Jun;4(3):411-24 [15161440.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2008 Feb;134(2):170-7 [18283160.001]
  • [Cites] Head Neck. 2004 Apr;26(4):322-30 [15054735.001]
  • [Cites] Otolaryngol Pol. 2006;60(5):729-36 [17263246.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 Dec;131(6):973-6 [15577800.001]
  • [Cites] Head Neck. 2002 Sep;24(9):821-9 [12211046.001]
  • [Cites] Ai Zheng. 2004 Nov;23(11 Suppl):1542-5 [15566676.001]
  • [Cites] Am J Otolaryngol. 1995 Mar-Apr;16(2):109-14 [7793504.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):719-30 [17543999.001]
  • [Cites] J Int Med Res. 2009 Jan-Feb;37(1):189-97 [19215690.001]
  • [Cites] Head Neck. 1995 Mar-Apr;17(2):114-8 [7558807.001]
  • [Cites] Am J Surg. 1989 Oct;158(4):328-32 [2802037.001]
  • [Cites] Rhinology. 1998 Mar;36(1):12-4 [9569435.001]
  • [Cites] Eur J Surg Oncol. 2005 Dec;31(10):1206-12 [15923101.001]
  • [Cites] J Otolaryngol. 2005 Dec;34(6):379-83 [16343397.001]
  • [Cites] Eur J Surg Oncol. 2007 Mar;33(2):222-8 [17127030.001]
  • [Cites] Acta Oncol. 2001;40(1):19-23 [11321654.001]
  • [Cites] Otolaryngol Pol. 2008;62(1):37-43 [18637419.001]
  • [Cites] Ir J Med Sci. 1995 Apr-Jun;164(2):139-41 [7607840.001]
  • [Cites] Head Neck. 2006 Oct;28(10):867-73 [16823871.001]
  • [Cites] Head Neck. 2005 Jul;27(7):575-84 [15825201.001]
  • [Cites] Otolaryngol Pol. 2007;61(4):572-5 [18260254.001]
  • (PMID = 19795137.001).
  • [ISSN] 1865-1569
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cobalt Radioisotopes; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 62
  •  go-up   go-down


13. Hatta C, Ogasawara H, Okita J, Kubota A, Ishida M, Sakagami M: Non-Hodgkin's malignant lymphoma of the sinonasal tract--treatment outcome for 53 patients according to REAL classification. Auris Nasus Larynx; 2001 Jan;28(1):55-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's malignant lymphoma of the sinonasal tract--treatment outcome for 53 patients according to REAL classification.
  • METHODS: Fifty-three patients with non-Hodgkin's malignant lymphoma (NHL) of the sinonasal tract were treated between 1981 and 1997.
  • The primary sites were the nasal cavity (67.8%), maxillary sinus (20.8%), ethmoidal sinus (9.4%), and frontal sinus (1.9%).
  • Based on the origin of the tumor cells, the authors classified NHL of the sinonasal tract into five groups with the REAL classification of Japan: diffuse large B-cell lymphoma (22.6%), peripheral T-cell lymphomas (15.1%), angiocentric lymphoma (35.9%), other lymphomas and unclassified types.
  • Of 53 patients, 39 (73.6%) received chemotherapy and radiotherapy, eight patients received chemotherapy alone, and four patients received radiotherapy alone.
  • The cumulative 5-year survival rates were 28.5% for all of the types, 55.0% for diffuse large B-cell lymphoma, 33.3% for peripheral T-cell lymphoma, and 19.7% for angiocentric lymphoma.
  • Results suggest that conventional combined treatment (CHOP chemotherapy+radiotherapy) is ineffective for NHL of the sinonasal tract, and especially so for NHL in the nasal cavity, NHL with tumor cells with positive T-cell markers, NHL further than Stage IIE and NHL with B symptoms.
  • CONCLUSION:. (1) In light of this ineffectiveness, new therapies must be developed to improve patient outcome instead of the conventional combined treatment;.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging / classification. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11137364.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NETHERLANDS
  •  go-up   go-down


14. Kumar S, Gupta AK, Yadav BS, Ghoshal S: Primary sinonasal malignant melanoma: a clinicopathologic and prognostic study. Ear Nose Throat J; 2009 Dec;88(12):1269-72
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sinonasal malignant melanoma: a clinicopathologic and prognostic study.
  • We conducted a retrospective study to evaluate the clinicopathologic features and prognostic factors associated with primary sinonasal malignant melanoma.
  • The tumors were located in the nasal cavity in 7 patients and in a paranasal sinus in the other 3.
  • Medial maxillectomy was performed in 4 patients, wide local excision in 3, and endoscopic excision in 2; the remaining patient, who had presented with a liver metastasis, received chemotherapy and palliative local radiotherapy.
  • Based on the findings of our small study, we conclude that primary sinonasal malignant melanoma carries a generally poor prognosis despite aggressive treatment.
  • Other factors that appeared to be associated with a poor prognosis were (1) older age, (2) a primary tumor location in a paranasal sinus, (3) an advanced tumor stage, (4) an external approach to surgery, and (5) the absence of adjuvant radiotherapy.
  • [MeSH-major] Melanoma / pathology. Melanoma / surgery. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013681.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Calaminus G, Schneider DT, Weissbach L, Schönberger S, Okpanyi V, Leuschner I, Poremba C, Göbel U: Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor. Klin Padiatr; 2009 May-Jun;221(3):136-40
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor.
  • Growing teratoma is still an often unsolved problem especially in male with mixed malignant GCTs of the testis or the mediastinum.
  • This specific situation with progressive tumor growth and simultaneous normalization of tumor markers during or after treatment of malignant GCTs with teratomatous elements is judged as a fatal situation if this situation can not be controlled by extensive surgery, as teratoma are not sensible to chemotherapy or irradiation.
  • Here, we report the case history of a 17-year old male patient with a testicular malignant GCT and wide spread lymph node metastases, who developed a rapidly progressive growing teratoma within the lymph node metastases.
  • Within the molecular profile of the tumor we could find a cytogenetic picture typically found in malignant adult GCTs.
  • In view of the bulky abdominal, thoracic and cervical metastases and the uncontrolled tumor progression, the situation was considered incurable.
  • However, following an individual treatment attempt, this patient was treated with a four-agent combination of drugs with antiangiogenetic potential as well as low-dose cyclic chemotherapy.
  • We therefore would like to highlight this treatment approach in unresectable growing teratoma and would like to stimulate further research and collaboration to come to an optimized treatment suggestion for this group of poor prognostic patients.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / surgery. Lymph Node Excision. Lymphatic Metastasis. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / surgery. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / surgery. Teratoma / drug therapy. Teratoma / surgery. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Bevacizumab. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Humans. Interferon-alpha / administration & dosage. Interferon-alpha / adverse effects. Lymph Nodes / blood supply. Lymph Nodes / pathology. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Recombinant Proteins. Reoperation. Salvage Therapy. Survival Rate. Thalidomide / administration & dosage. Thalidomide / adverse effects. Tomography, X-Ray Computed. Vinblastine / administration & dosage. Vinblastine / adverse effects

  • Genetic Alliance. consumer health - Malignant germ cell tumor.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Klin Padiatr. 2009 May-Jun;221(3):134-5 [19437359.001]
  • (PMID = 19437360.001).
  • [ISSN] 1439-3824
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Interferon-alpha; 0 / Recombinant Proteins; 2S9ZZM9Q9V / Bevacizumab; 4Z8R6ORS6L / Thalidomide; 5V9KLZ54CY / Vinblastine; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


16. Popadiuk S, Korzon M, Szumera M, Chybicka A, Szmyd K, Dzierzega M, Kowalczyk JR, Wiśniewska-Slusarz H, Trelińska J, Wozniak W, Bilska K, Wysocki M, Krawczuk-Rybak M, Lopatka B: [Malignant germ cell tumours. Multicenter prospective trial in Polish Pediatric Group for Solid Tumours (years 1998-2000)]. Przegl Lek; 2004;61 Suppl 2:29-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant germ cell tumours. Multicenter prospective trial in Polish Pediatric Group for Solid Tumours (years 1998-2000)].
  • Diagnosis was made on histopathological examination in 88% patients (pts) and in 12% was established on imaging and biochemical findings (elevated AFP).
  • Mixed germ cell tumor and yolk sac tumor prevelaged.
  • Primary tumor was localized in gonads (59%) and in sacrococcygeal region (30%).
  • 77 children completed therapy, 15 continue treatment and 3 were lost from follow-up.
  • RESULTS: Among children who were off therapy, 70 (91%) are alive in a complete remission (second remission in 3 cases).
  • Median time of follow-up is 31 months from the beginning of treatment and 25 months after completion of therapy.
  • CONCLUSION: The outcome of malignant germ cell tumors treatment in Poland is favourable and comparable to results showed by other study groups in the world.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / surgery. Female. Humans. Infant. Male. Neoplasm Invasiveness. Neoplasm Staging. Poland. Prospective Studies. Survival Analysis. Time Factors. Treatment Outcome. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15686043.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


17. Lee KH, Lee IH, Kim BG, Nam JH, Kim WK, Kang SB, Ryu SY, Cho CH, Choi HS, Kim KT, Korean Gynecologic Oncology Group: Clinicopathologic characteristics of malignant germ cell tumors in the ovaries of Korean women: a Korean Gynecologic Oncology Group Study. Int J Gynecol Cancer; 2009 Jan;19(1):84-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics of malignant germ cell tumors in the ovaries of Korean women: a Korean Gynecologic Oncology Group Study.
  • We evaluated the clinicopathologic characteristics of malignant germ cell tumors in the ovaries of South Korean women and determined the prognostic factors affecting recurrence.
  • Histologically, immature teratoma was the most common tumor type (n = 68), followed by dysgerminoma (n = 54), endodermal sinus tumor (n = 38), mixed form (n = 24), and choriocarcinoma (n = 12).
  • A fertility-sparing operation was performed in 134 patients, staging operation in 43 patients, and hysterectomy and bilateral salpingo-oophorectomy in 19 patients.
  • Postoperative chemotherapy was administered in 166 patients, and the most common regimen was bleomycin, etoposide, and cisplatin (n = 120).
  • Recurrence was observed in 13 patients (6.8%) and was influenced by the stage of the tumor and patient age (>40 years).
  • The results of this study demonstrate that most malignant germ cell tumors of the ovary in Korean women are detected in the early stage and have excellent survival outcomes with conservative operation and platinum-based chemotherapy.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Korea. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258947.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Lee JK; Park JJ; Cha MS; Kim JH; Lee JM; Park SY; Kim SC; Lee SK
  •  go-up   go-down


18. Low JJ, Perrin LC, Crandon AJ, Hacker NF: Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer; 2000 Jul 15;89(2):391-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases.
  • BACKGROUND: Effective combination chemotherapy has improved the previously dismal prognosis for malignant ovarian germ cell tumors (MOGCT) dramatically.
  • In young patients, conservative surgery with adjuvant chemotherapy has made the preservation of fertility possible, even in patients with advanced disease.
  • METHODS: The current study is a retrospective review of 74 patients with MOGCT treated by conservative surgery, retaining the uterus and contralateral ovary to preserve ovarian function, with or without chemotherapy.
  • The histologic subtypes included 31 dysgerminomas (41.9%), 16 immature teratomas (21.6%), 13 endodermal sinus tumors (17.6%), 11 mixed germ cell tumors (14.9%), and 3 embryonal cell tumors (4.1%).
  • Adjuvant chemotherapy was administered in 47 patients (63.5%).
  • During chemotherapy 61.7% of patients developed amenorrhea but 91.5% of these women resumed normal menstrual function on completion of chemotherapy.
  • Fourteen healthy live births were recorded in the chemotherapy group and there were no documented birth defects.
  • The majority of these patients who have received combination chemotherapy resume normal ovarian function and can expect a normal fertility rate and healthy offspring.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Cohort Studies. Cystectomy / methods. Female. Follow-Up Studies. Humans. Menstruation. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Omentum / surgery. Ovariectomy / methods. Reproduction. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10918171.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


19. Oskouian RJ Jr, Jane JA Sr, Dumont AS, Sheehan JM, Laurent JJ, Levine PA: Esthesioneuroblastoma: clinical presentation, radiological, and pathological features, treatment, review of the literature, and the University of Virginia experience. Neurosurg Focus; 2002 May 15;12(5):e4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma: clinical presentation, radiological, and pathological features, treatment, review of the literature, and the University of Virginia experience.
  • Esthesioneuroblastoma is a rare and malignant upper nasal cavity neoplasm involving the anterior skull base.
  • Treatment includes surgery, radiotherapy, chemotherapy, or a combination.
  • The ideal treatment modality has yet to be determined.
  • Resection risks damaging these critical structures, and radiotherapeutic techniques, similar to those applied for paranasal sinus tumors, may damage these vital structures and result in late sequelae such as blindness and cortical necrosis.
  • Management strategies for this neoplasm lack uniformity, and there is no universally accepted staging system.
  • In this paper the authors discuss the clinical presentation, radiological and pathological features, and treatment of this rare, malignant skull base neoplasm, as well as review the literature.
  • They also present their results and treatment regimen, which includes preoperative radio- and chemotherapy or 1) craniofacial resection if the lesion has a significant intracerebral component, or 2) frontal sinus resection if little intracranial extension exists.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Postoperative Complications. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119902.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 71
  •  go-up   go-down


20. Knott PD, Gannon FH, Thompson LD: Mesenchymal chondrosarcoma of the sinonasal tract: a clinicopathological study of 13 cases with a review of the literature. Laryngoscope; 2003 May;113(5):783-90
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: Mesenchymal chondrosarcoma of the sinonasal tract is a rare, malignant tumor of extraskeletal origin.
  • The maxillary sinus was the most common site of involvement (n = 9), followed by the ethmoid sinuses (n = 7) and the nasal cavity (n = 5).
  • All cases were managed by surgery with adjuvant radiation therapy (n = 4) and/or chemotherapy (n = 3).
  • The overall mean survival was 12.1 years, although five of six patients who developed local recurrences died of disease (mean survival, 6.5 y).
  • CONCLUSIONS: Mesenchymal chondrosarcoma of the sinonasal tract is an aggressive tumor with a predilection for young women.
  • Aggressive, exenterative surgery combined with adjuvant therapy appears to yield the best clinical outcome.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / pathology. Chondrosarcoma, Mesenchymal / radiography. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / radiography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12792311.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


21. Michael H, Lucia J, Foster RS, Ulbright TM: The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol; 2000 Feb;24(2):257-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 91 men had histologically documented late recurrences of testicular germ cell tumors characterized by a complete response to treatment with a subsequent disease-free interval of at least 2 years and no evidence of a second primary lesion.
  • Ninety percent of the patients for whom information was available received chemotherapy shortly after their initial diagnosis of testicular germ cell tumors; most of the other patients were known to have stage I disease initially.
  • Thus, teratoma was the most common type of neoplasm in late recurrences.
  • Excluding teratoma coexisting with other types of neoplasms, yolk sac tumor was the most frequent type of tumor in patients with late recurrence.
  • It occurred in 47% of patients, either alone or with teratoma, another nonteratomatous germ cell tumor type, or a "nongerm cell malignant tumor."
  • Unusual types of yolk sac tumor, including glandular, parietal, clear cell, and pleomorphic patterns, were seen frequently in late recurrences and often raised differential diagnostic problems with "nongerm cell" carcinomas.
  • A smaller number of late recurrences consisted of other types of neoplasms.
  • Twenty percent of patients with late recurrence had a nonteratomatous germ cell tumor other than yolk sac tumor, either alone, with yolk sac tumor, or with a "nongerm cell malignant tumor."
  • Most of these nonteratomatous germ cell tumors other than yolk sac tumor were embryonal carcinoma, although rarely seminoma and choriocarcinoma were encountered.
  • "Nongerm cell malignant tumors," including both sarcomas and carcinomas of various types, occurred in 23% of late-recurrence patients, either alone or with a nonteratomatous germ cell tumor.
  • Patients whose late recurrences consisted of pure "nongerm cell malignant tumor" or pure germ cell tumor (yolk sac tumor or other types) had a much worse prognosis: Only 36% to 37% were alive with no evidence of disease.
  • Patients with two different types of nonteratomatous malignancies in their late recurrences had a dismal clinical course: Only 17% with both yolk sac tumor and other nonteratomatous germ cell tumor had no evidence of disease, whereas no patient with both nonteratomatous germ cell tumor and "nongerm cell malignant tumor" was disease free.
  • Furthermore, late recurrence is not likely to respond to chemotherapy and is best treated by surgical excision when possible.
  • [MeSH-major] Germinoma / pathology. Neoplasm Recurrence, Local / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Embryonal / complications. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / therapy. Choriocarcinoma / complications. Choriocarcinoma / pathology. Choriocarcinoma / therapy. Endodermal Sinus Tumor / complications. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Fluorescent Antibody Technique, Direct. Humans. Male. Neoplasm Staging. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Sarcoma / complications. Sarcoma / pathology. Sarcoma / therapy. Seminoma / complications. Seminoma / pathology. Seminoma / therapy. Teratoma / complications. Teratoma / pathology. Teratoma / therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10680894.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


22. Iseh KR, Aliyu D: Surgical considerations in the management of tumours of the nose and paranasal sinuses in a Northern Nigerian Teaching Hospital. West Afr J Med; 2009 Nov-Dec;28(6):371-5
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 46(83.6%) patients the tumours had extended beyond the nasal cavity or one sinus cavity to contiguous structures.
  • The surgical operations carried out were lateral rhinotomy in 37(57.8%), intranasal clearance and intranasal antrostomy in 16(25%), total maxillectomy in seven(11%), and anterior craniofacial resection in two (3.1%) patients.The histological examination showed that 43 (78.2%) cases were benign, while 12 (21.8%) cases were malignant.
  • These malignant cases needed radiotherapy and chemotherapy.
  • Provision of free medical care and modern facilities for early diagnosis, treatment, and health education are needed to reverse the trend.
  • [MeSH-major] Nose Neoplasms / surgery. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Child, Preschool. Female. Follow-Up Studies. Hospitals, Teaching. Humans. Male. Middle Aged. Neoplasm Staging. Nigeria / epidemiology. Otorhinolaryngologic Surgical Procedures / methods. Sex Distribution. Socioeconomic Factors. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20486095.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


23. Chen CH, Chen TC, Huang WC, Chen TY, Liu HC: An unusual successfully treated case of pulmonary yolk sac tumor. Ann Thorac Surg; 2008 Feb;85(2):656-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual successfully treated case of pulmonary yolk sac tumor.
  • Extragonadal germ cell tumors are relatively rare, particularly malignant yolk sac tumors arising in the lung parenchyma.
  • We report a case of a huge malignant yolk sac tumor in the right middle lobe.
  • The patient was successfully treated with neoadjuvant chemotherapy followed by complete resection of the tumor.
  • [MeSH-major] Endodermal Sinus Tumor / surgery. Lung Neoplasms / surgery. Neoadjuvant Therapy. Pneumonectomy / methods
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Risk Assessment. Thoracotomy / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18222293.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Peng RQ, Wu GH, Chen WK, Ding Y, Ma J, Zhang NH, Su YS, Zhang XS: [Clinical characteristics and prognosis of primary nasal mucosal melanoma--a report of 44 cases]. Ai Zheng; 2006 Oct;25(10):1284-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Primary mucosal malignant melanoma of the nasal cavity, paranasal sinuses, and nasopharynx is rare and current research data of this disease are mainly from western populations.
  • Demographics and baseline characteristics, treatments, recurrence, metastasis, and survival were documented in hospital records.
  • Of the 31 patients received operation-dominated treatment, 8 received adjuvant radiotherapy, 13 received adjuvant chemotherapy, and 6 received adjuvant non-specific immunotherapy.
  • The median time of follow-up was 29 months.
  • The median survival time was 24 months and the 5-year survival time was 25%.
  • Clinical stage affected prognosis, whereas age, gender, site, primary tumor mass, and adjuvant therapy were not correlated to survival status.
  • [MeSH-major] Melanoma. Nasal Mucosa. Neoplasm Recurrence, Local. Nose Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Nasal Cavity. Neoplasm Staging. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / surgery. Paranasal Sinus Neoplasms / therapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059777.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


25. Ross JH, Rybicki L, Kay R: Clinical behavior and a contemporary management algorithm for prepubertal testis tumors: a summary of the Prepubertal Testis Tumor Registry. J Urol; 2002 Oct;168(4 Pt 2):1675-8; discussion 1678-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical behavior and a contemporary management algorithm for prepubertal testis tumors: a summary of the Prepubertal Testis Tumor Registry.
  • PURPOSE: The Prepubertal Testis Tumor Registry was established by the Urologic Section of the American Academy of Pediatrics in 1980 to record data on a large number of prepubertal testis tumors regarding presentation, treatment and outcome to define appropriate management better.
  • MATERIALS AND METHODS: Relevant data in the prepubertal testis tumor registry were tabulated and analyzed.
  • RESULTS: There were 395 prepubertal patients who had a primary testis tumor.
  • A significant proportion of tumors were benign regardless of patient age. alpha-Fetoprotein levels for patients with benign and malignant tumors overlapped in children younger than 6 months.
  • Of the patients with yolk sac tumor 80% presented with stage 1 disease and overall survival was excellent.
  • Of all patients with stromal tumors metastases developed in only 1.
  • Patients with stage I yolk sac tumor should be monitored closely, and those with recurrent or metastatic yolk sac tumor should be treated with chemotherapy.
  • Retroperitoneal lymph node dissection is reserved for patients with recurrent retroperitoneal masses following chemotherapy.
  • Aggressive treatment of metastatic Sertoli cell or undifferentiated stromal tumors is warranted.
  • [MeSH-minor] Algorithms. Child. Child, Preschool. Combined Modality Therapy. Endodermal Sinus Tumor / congenital. Endodermal Sinus Tumor / mortality. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / therapy. Humans. Infant. Male. Neoplasm Staging. Prognosis. Sertoli Cell Tumor / congenital. Sertoli Cell Tumor / mortality. Sertoli Cell Tumor / pathology. Sertoli Cell Tumor / therapy. Sex Cord-Gonadal Stromal Tumors / congenital. Sex Cord-Gonadal Stromal Tumors / mortality. Sex Cord-Gonadal Stromal Tumors / pathology. Sex Cord-Gonadal Stromal Tumors / therapy. Survival Rate. United States. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12352332.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


26. Paulino AF, Singh B, Shah JP, Huvos AG: Basaloid squamous cell carcinoma of the head and neck. Laryngoscope; 2000 Sep;110(9):1479-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE/HYPOTHESIS: Basaloid squamous cell carcinoma (BSCC), an uncommon tumor with predilection for the upper aerodigestive tract, is a distinct variant of squamous carcinoma, because of its unique histological features and ominous clinical behavior.
  • Sites of origin included the larynx (4), tongue (3), pyriform sinus (3), nose (2), floor of mouth (2), mastoid (1), tonsil (1), epiglottis (1), nasopharynx (1), trachea (1), and palate (1).
  • Treatment modalities included surgery with or without chemotherapy or radiotherapy in 13 patients, chemotherapy with irradiation in 2, chemotherapy alone in 2, and radiotherapy alone in 3.
  • Four were alive with disease at the time of writing and five died of disease.
  • CONCLUSION: BSCC is a highly aggressive malignant tumor that presents in elderly patients who have a history of abuse of tobacco or alcohol, or both.
  • Greater number of patients must be studied and compared with age-matched and stage-matched controls of conventional squamous cell carcinoma to determine whether the poor clinical outcome is related more to high-stage presentation or to the tumor's high-grade malignant cytological features.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10983946.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


27. Yamamoto R, Hosokawa S, Yamatodani T, Morita S, Okamura J, Mineta H: [Eight cases of neuroendcrine carcinoma of the head and neck]. Nihon Jibiinkoka Gakkai Kaiho; 2008 Jul;111(7):517-22
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small cell neuroendocrine carcinoma of the head and neck is rare, and diagnosis may be difficult.
  • Three cases arose from the maxillary sinus, two from the ethmoid sinus, one from the parotid gland, one from the tonsil, and one from the larynx.
  • Histological analysis by hematoxylin-eosin staining tentatively revealed malignant lymphoma and undifferentiated carcinoma in two cases each, while immunohistological and/or electron microscopy analysis confirmed histological diagnosis.
  • All were treated by chemotherapy (VP-16, CDDP) and seven cases with radiotherapy based on the schedule of small cell carcinoma of the lung and two cases with lesional resection.
  • Chemotherapy and radiotherapy were effective locally.
  • Long-term survival thus requires the effective treatment of distant metastasis.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Epirubicin / administration & dosage. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697475.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; PE regimen
  •  go-up   go-down






Advertisement